BPC-157
What is BPC-157
BPC-157, which stands for Body Protection Compound 157, is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protective protein naturally found in human gastric juice. It is one of the most researched peptides in the field of regenerative medicine and healing. Unlike many peptides that target a single system, BPC-157 has demonstrated a remarkably broad range of regenerative effects across multiple tissues and organ systems. It has been studied extensively for its ability to accelerate healing in muscles, tendons, ligaments, bones, and the gastrointestinal tract. BPC-157 is considered a stable gastric pentadecapeptide, meaning it remains stable in human gastric juice, an unusual property that has made it particularly interesting to researchers studying gut health and systemic healing. While BPC-157 has not yet received FDA approval, it has been the subject of a substantial body of preclinical research and is widely studied for its regenerative, anti-inflammatory, and neuroprotective properties.
History & Discovery
BPC-157 was first identified and isolated in the early 1990s by a research team led by Dr. Predrag Sikiric at the University of Zagreb in Croatia. The compound was derived from a naturally occurring protective protein found in human gastric juice, a protein the body uses to protect and repair the lining of the stomach. Dr. Sikiric and his team were studying the cytoprotective properties of gastric juice, specifically why the stomach lining is able to withstand the highly acidic environment it operates in, when they isolated the peptide sequence that would become known as BPC-157. Early animal studies conducted throughout the 1990s and 2000s produced remarkable results. BPC-157 demonstrated an ability to accelerate the healing of a wide range of tissues including muscles, tendons, ligaments, bones, and the gastrointestinal tract at a rate that consistently exceeded control groups. What made these findings particularly notable was the breadth of BPC-157's effects. Most healing compounds show specificity, they work well on one tissue type. BPC-157 appeared to work across multiple systems simultaneously, prompting researchers to investigate the underlying mechanisms driving this unusually broad regenerative profile. Research into BPC-157 has continued steadily since its discovery, with Dr. Sikiric's team at the University of Zagreb remaining among the most prolific publishers of BPC-157 research in the world. To date it has been studied in numerous animal models across a wide range of conditions, establishing one of the most extensive preclinical research profiles of any peptide in the field.
How it Works
BPC-157 works through several interconnected mechanisms that collectively contribute to its broad regenerative and protective effects.Â
Angiogenesis - Building New Blood Vessels One of BPC-157's most well-documented mechanisms is its ability to stimulate angiogenesis, the formation of new blood vessels. By upregulating VEGF (Vascular Endothelial Growth Factor), BPC-157 accelerates the development of new vascular networks in damaged tissue. This is critical for healing because blood vessels deliver the oxygen and nutrients tissues need to repair themselves.
​
Nitric Oxide System Modulation - BPC-157 interacts with the nitric oxide (NO) system, which plays a central role in vascular function, inflammation regulation, and tissue repair. By modulating nitric oxide pathways, BPC-157 helps regulate blood flow to damaged areas and supports the body's natural inflammatory response.
​
Growth Hormone Receptor Upregulation - BPC-157 has been shown to upregulate growth hormone receptors in tendon fibroblast, the cells responsible for producing and maintaining connective tissue. This makes tissues more responsive to the body's own growth hormone, accelerating the repair of tendons and ligaments.
​
Gut-Brain Axis Interaction - BPC-157 interacts with the gut-brain axis, the communication network between the gastrointestinal tract and the central nervous system. This interaction contributes to its protective effects on both gut tissue and neurological function, and may explain its observed effects on mood and stress response in preclinical models.
​
Cytoprotection & Anti-Inflammatory Effects Derived from a gastric protective protein, BPC-157 exhibits strong cytoprotective properties, meaning it actively protects cells from damage. It has demonstrated the ability to counteract damage caused by NSAIDs, alcohol, and other harmful substances in the gastrointestinal tract, while simultaneously reducing systemic inflammation through multiple pathways. The combination of these mechanisms is what gives BPC-157 its unusually broad therapeutic profile. Rather than targeting a single pathway, it works across multiple systems simultaneously, making it one of the most versatile peptides studied in regenerative medicine.
Safety & Considerations
BPC-157 has one of the most extensive preclinical research profiles of any peptide studied in regenerative medicine, with over three decades of animal studies consistently demonstrating regenerative, anti-inflammatory, and cytoprotective effects. However, human clinical data remains limited. As of 2025, only three small pilot studies have been conducted in humans, involving fewer than 30 total participants across all three studies. Importantly, no adverse events were reported in any of them. Regulatory Status It is important to understand where BPC-157 currently stands from a regulatory perspective:
— In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be legally compounded for human use in the United States under current regulations
— In 2022, WADA (World Anti-Doping Agency) banned BPC-157 under the S0 Unapproved Substances category, prohibiting its use by competitive athletes in and out of competition
— No regulatory agency worldwide has formally approved BPC-157 for human therapeutic use
​
Theoretical Side Effects Based on preclinical research and known mechanisms, the following theoretical side effects have been discussed in the scientific literature:
— Pathologic angiogenesis, BPC-157 upregulates VEGF and related pathways. While BPC-157 has actually been shown to inhibit uncontrolled cell proliferation in studies, the theoretical concern about angiogenesis in cancer contexts deserves acknowledgment — Nitric oxide overproduction at high doses may interfere with hemoglobin formation and alter drug metabolism
— Proline metabolite production, a primary breakdown product of BPC-157, may contribute to oxidative stress at elevated levels
​
Who should use caution or avoid BPC-157:
— Not recommended during pregnancy or breastfeeding
— Individuals with active cancer or a history of cancer should consult their healthcare provider before use given the theoretical angiogenic concerns
— Those on medications affecting blood pressure, clotting, or immune function should consult their healthcare provider before starting
— Competitive athletes should be aware of BPC-157's WADA prohibited status
​
A Note on Transparency At Resilience EQ, we believe you deserve the full picture. BPC-157's animal research is among the most compelling in peptide science. The limited human data available is promising. But the honest truth is that large-scale human trials have not yet been completed, and the regulatory landscape reflects that reality. We present this information not to discourage, but because an educated customer is always a safer one.
If any adverse reactions occur, discontinue use immediately and consult a healthcare provider.
Sources
1. Sikiric, P. et al. (1994). The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions. Life Sciences, 54, PL63–68. https://pubmed.ncbi.nlm.nih.gov/8295260/
​
2. Gwyer, D., Wragg, N.M. & Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377, 153–159. https://pubmed.ncbi.nlm.nih.gov/31055660/
​
3. Seiwerth, S. et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. https://pmc.ncbi.nlm.nih.gov/articles/PMC7996379/
​
4. McGuire, F.P. et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
​
5. Vasireddi, N. et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Sports Health. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
​
6. Lee, E. & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27. https://pubmed.ncbi.nlm.nih.gov/32721886/
​
7. Lee, E., Walker, C. & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30, 12–17. https://pubmed.ncbi.nlm.nih.gov/37862641/
​
8. Xu, C. et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 114, 104665. https://pubmed.ncbi.nlm.nih.gov/32234512/
​
9. Jozwiak, M. et al. (2025). Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals, 18(2), 185. https://www.mdpi.com/1424-8247/18/2/185
​
10. FDA. (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
The following information is based on published third-party research and is provided for educational purposes only. It does not represent the effects of any Resilience EQ product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.